News
Pfizer, Moderna Boost Hopes But Many Nations Counting On Oxford Vaccine
Trial successes from Pfizer Inc. and Moderna Inc. have buoyed hopes that a Covid-19 vaccine is coming soon. But much of the world, outside of rich nations like the U.S., is counting on another company's shot to escape the...
News
Russia Says Its Sputnik V COVID-19 Vaccine 95% Effective
Russia's Sputnik V coronavirus vaccine is 95 percent effective according to a second interim analysis of clinical trial data, its developers said on Tuesday. The two-dose vaccine will be available on international markets for less than $10 (8.40 euros)...
News
Government of Canada signs new agreement for a COVID-19 antibody therapy
The Government of Canada is taking steps to provide Canadians with effective therapies as part of its response to COVID-19. The Honourable Anita Anand, Minister of Public Services and Procurement and the Honourable Patty Hajdu, Minister of Health, announced...
News
Regeneron’s REGEN-COV2 is First Antibody Cocktail for COVID-19 to Receive FDA EUA
Regeneron Pharmaceuticals, Inc. announced that the antibody cocktail casirivimab and imdevimab administered together (also known as REGN-COV2 or REGEN-COV2), a therapy currently being investigated for use in COVID-19, has received Emergency Use Authorization (EUA) from the U.S. FDA. Casirivimab...
Drug Research
CureVac and WACKER Sign Manufacturing Contract for CureVac’s COVID-19 Vaccine Candidate
CureVac N.V., a biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA), and Wacker Chemie AG announced that they had signed a contract for the manufacturing of CureVac’s COVID-19 vaccine candidate CVnCoV. Under...
Clinical Trials
Astrazeneca Says AZD1222 vaccine met primary efficacy endpoint in preventing COVID-19
Positive high-level results from an interim analysis of clinical trials of AZD1222 in the UK and Brazil showed the vaccine was highly effective in preventing COVID-19, the primary endpoint, and no hospitalisations or severe cases of the disease were...
News
Lillys neutralizing antibody bamlanivimab receives interim authorization from Health Canada as a treatment for COVID-19
Health Canada granted authorization under the Interim Order Respecting the Importation, Sale and Advertising of Drugs for Use in Relation to COVID-19 for the use of bamlanivimab (LY-CoV555) as a treatment for adults and pediatric patients 12 years of...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read
















